Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Multiple Myeloma 30Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Graft vs Host Disease 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma 24Leukemia 24Hematologic Neoplasms 20Neoplasms 18Lymphoma, Mantle-Cell 18Sarcoma 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 17Tuberous Sclerosis 15Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Burkitt Lymphoma 14Waldenstrom Macroglobulinemia 13Lymphoma, B-Cell, Marginal Zone 13Recurrence 12Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Primary Myelofibrosis 11Melanoma 11Leukemia, Myelomonocytic, Chronic 11

Interventions

ibrutinib 9tofacitinib 7Imatinib Mesylate 5ruxolitinib 4ofatumumab 4Rituximab 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Sirolimus 3Mycophenolic Acid 3Cyclophosphamide 3Blood Specimen Collection 3obinutuzumab 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Filgrastim 2Alemtuzumab 2ziconotide 1sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Sirolimus × Clear all
NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05327023 2026-04-28

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
430 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡